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Abstract: The molecular properties of compounds expressing growth inhibition of Mycobacterium tuberculosis 
are determined and examined for underlying relationships by pattern recognition methods.  Pattern recognition 
methods such as hierarchical cluster analysis will show relationships between compounds.  Descriptive 
statistical analysis of molecular properties reveal commonality among bacteriostatic compounds. Outliers 
within any category of descriptor is identified by Grubb’s test.  Potency of growth inhibition measured as MIC 
(minimum inhibitory concentration) after in vitro evaluation will be compared and analyzed.  Structure moieties 
and their effect on activity is identified. All compounds analyzed showed substantial growth inhibition of 
Mycobacterium tuberculosis, having MIC values ranging from 16.7 µgrams/milliliter to 65.9 µgrams/milliliter 
(isoniazid MIC at 14.7 µgrams/milliliter).  Ranges in values of Log P, number of atoms, and molecular weight 
were, respectively: -1.89 to 1.10, 11 to 25 (isoniazid at 10), and 150.18 grams/mole to 345.38 grams/mole 
(isoniazid at 137.14).  All eight compounds and isoniazid showed favorable bioactivity within six categories of 
measureable bioactivity scores. The molecular properties of eight compounds and isoniazid varied, however, 
remained favorable in drug-likeness with zero violations of the Rule of 5. Interrelationships of the descriptors 
were revealed by statistical analysis.  
Keywords: Mycobacterium tuberculosis, tuberculostats, hydrazide, antimicrobial  
 
I. Introduction 
Up to 3 million deaths due to Mycobacterium tuberculosis are thought to occur each year, along with 
up to 8 million new cases of infection [1].  With nearly one-third of the world’s population believed to be 
infected with Mycobacterium tuberculosis, several outbreaks of multidrug resistant tuberculosis were observed 
during the 1990’s in Europe and the United States [1]. Multidrug-resistant tuberculosis (MDR-TB) is defined to 
be bacilli resistant to at least two members of the first-line tuberculostats, notably isoniazid and rifampin [2]. In 
2008, up to 510000 cases of MDR-TB or 3.6% of all incidents, were observed across the globe [2]. Treatment of 
MDR-TB is more difficult, less effective, and even more than 100 times costlier than drug susceptible 
tuberculosis [2].  Isoniazid is a crucial member of the first-line combination therapy regimen of tuberculosis 
treatment [2].The description of extensively drug-resistant tuberculosis (XDR-TB) are those incidents of 
infection resistant to isoniazid, rifampin, any fluoroquinolone, and at least one second-line drug (amikacin, 
kanamycin, capreomycin) [3].  XDR-TB is more difficult to treat and has been identified in 46 countries by 
2008 [3].  In 2006 as many as 200000 individuals, co-infected with HIV, died of complications with 
tuberculosis [3]. 
There is an urgent necessity to improve clinical treatment of tuberculosis, by improving the application 
of existing drugs and/or development of new agents [4]. The definition of first-line treatment agents includes 
rifampin, isoniazid, pyrazinamide, and ethambutol, which are taken over a period of at least six months to 
acquire high cure rates of more than 95% [4].  Adverse effects to anti-tuberculosis drugs are commonly seen and 
contribute to problem of patient adherence to therapy [4]. Second-line agents are even more toxic, less effective, 
and require even longer use than first-line agents [4]. MDR-TB treatment requires the application of the more 
expensive second-line agents for at least 18 months [5, 6].  A rise of the number of incidents of retreatment 
results in the increase of drug-resistance in any region [7].  By 2009, it was estimated that 11.1% of new cases 
of tuberculosis demonstrated resistance to any drug with that figure rising to 25.1% in cases of previous 
treatment [8]. The clinical outcome for patients harboring XDR-TB is even worse than that for MDR-TB [9], is 
spread through the air like other forms of tuberculosis [10], and shows a much higher mortality rate that MDR-
TB [11]. Tuberculosis infection is a health threat having significant morbidity and mortality, with up to 1.5 
million deaths annually [12]. Drug-resistant strains of bacterial tuberculosis have increased, as well as viral HIV 
co-infection with tuberculosis [12]. Up to one-third of the world’s population is thought to be infected with 
Mycobacterium tuberculosis [13, 14].  Notably, each year up to 8.8 million patients are newly diagnosed with an 
active infection of tuberculosis [14]. To complicate and make more difficult the clinical treatment of 
tuberculosis, the current first-line drugs for treatment (isoniazid, rifampin, pyrazinamide, ethambutol) must be 
taken for up to 6 months to achieve high level of cure rates (>95%) [14].  Therefore, the study and development 
of new drugs is vital for the clinical treatment of tuberculosis. 
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II. Materials And Methods 
Properties and Molecular Modeling  
Various numerical values of molecular properties (descriptors) of compound structures were 
accomplished by utilizing Molinspiration (Molinspiration Cheminformatics, Nova ulica 61, SK-900 26 
Slovensky Grob, Slovak Republic).  Determination of molecular structure components was accomplished by 
utilizing ACD ChemSketch Modeling v. 12.01 (Advanced Chemistry Development, 110 Yonge Street, Toronto 
Ontario, M5C 1T4 Canada, http://www.molinspiration.com/services/search.html). Determination of drug-
likeness scores for kinase inhibitor, protease inhibitor, and enzyme inhibitor, etc., was determined by 
Molinspiration Cheminformatics (http://www.molinspiration.com/cgi-bin/properties). 
 
Pattern Recognition and Multivariate Analysis  
Various pattern recognition techniques to identify underlying associations and patterns within the 
numerical properties utilizing hierarchical cluster analysis accomplished by KyPlot v. 2.0 Beta 15 (copyright 
Koichi Yoshioka 1997-2001).  Analysis of one-way ANOVA and 95% ellipses was performed by PAST v. 2.06 
(copyright Oyvind Hammer, D.A.T. Harper 1999-2008). Path analysis is accomplished by OpenStat (copyright 
William Miller, September 11, 2008).  
 
Various Statistical Analysis  
Other statistical analysis of numerical data that includes Pearson r correlation and various descriptive 
statistics was accomplished by Microsoft EXCEL v. 14.0.6112.5000 (EXCEL Professional plus 2010).  Multiple 
regression analysis of molecular property values was accomplished utilizing GraphPad Instat version 3.00 
(GraphPad Software, Inc., San Diego California USA; www.graphpad.com).  Identification of numerical 
outliers was accomplished by Grubb’s test (extreme studentized deviate), with the t-test to compare two means 
was done by (http://www.graphpad.com/quickcalcs/).   
 
III. Results And Discussion 
Structure and Properties    
The development of new tuberculostats are of great importance on account the appearance of multi-
drug resistant, extensively drug resistant, and totally drug resistant tuberculosis [2,3].  In this investigation, a 
group of novel hydrazide compounds have been compared to the first-line drug isoniazid for effectiveness of 
Mycobacterium tuberculosis inhibition. The effectiveness of inhibition is measured by in vitro method in which 
various compounds are added in known increasing concentration [15, 16].Molecular structures of all compounds 
tested in vitro and evaluated in this study [15, 16], are presented in Figure 1 for comparison to the first-line drug 
isoniazid (compound 9) and other hydrazide compounds.  Notably, a characteristic of all the compounds shown, 
is the hydrazide group (-C(=O)-NHNH2) that is a substituent for all molecular structures. All compounds 
presented in Figure 1 have one aromatic ring (containing a conjugated planar ring system), with various 
substituents covalently bonded onto the aromatic ring  (see Figure 1).   
In addition to the hydrazide group, the compounds 1 to 9 have various substituents.  Compound 1 has a 
methyl group substituent (-CH3) in meta position to the hydrazide group. Compound 2 with acetate (-
OC(=O)CH3) group in meta position to hydrazide. Compound 3 has a chloromethyl group (-CH2Cl) to 
hydrazide. Compound 4 has a single nitro group (-NO2) in para position relative to the hydrazide. Compound 5 
has a bromine atom in ortho position relative to hydrazide. Compound 6 has a bromine atom in the meta 
position to hydrazide. Compound 7 has a bromine atom in the para position relative to the hydrazide. Compound 
8 is ciprofloxacin having a hydrazide group in place of the original carboxyl group (-C(=O)OH). Compound 9 is 
the first-line tuberculostat isoniazid.  
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Figure 1 Molecular structures of hydrazide compounds that inhibit Mycobacterium tuberculosis with IUPAC 
designation and SMILES notation. 
 
The effects of various substituent groups covalently bound to the aromatic ring within these 
compounds influences the molecular properties (Log P, polar surface area, molecular weight, etc) and thereby 
the bioavailability (the fraction of an administered dose of unchanged drug that reaches the systemic circulation) 
of a potential drug [17, 18].  Drug-likeness is a qualitative concept used in drug design as a measure of how 
drug-like a substance is with respect to factors like bioavailability [17].  
Physical properties of the drug affect the bioavailability of any drug [17].  Various molecular properties 
have been shown to be highly useful for evaluating the drug-likeness of a potential drug and various screening 
parameters assist in identifying compounds for advanced development [17, 18, 19].  The Rule of 5 is a screening 
test to determine if a chemical compound with a certain biological activity has properties that would make it 
orally active in humans [17, 18].  This rule states that, in general, an orally active drug has no more than one 
violation of the following criteria [17, 18]: 1) No more than 5 hydrogen bond donors (total number of nitrogen–
hydrogen and oxygen–hydrogen bonds); 2) No more than 10 hydrogen bond acceptors (all nitrogen and oxygen 
atoms); 3) A molecular mass less than 500 grams/mole; and 5) An octanol-water partition coefficient log P not 
greater than 5.  Another screening test for favorable drug-likeness is condensed to meet only two rules [19]: 1) 
Ten or fewer rotatable bonds, and 2) Polar surface area less than 140 Angstroms
2
.  All compounds 1 to 9 show 
zero violations of the Rule of 5 (see Table 1), indicating favorable drug-likeness and bioavailability [17].The 
molecular properties of all nine compounds are listed in Table 1 and show the diverse effects of various 
substituents on molecular properties and consequently the drug-likeness of these compounds. 
 
Table 1 Molecular Properties of Compounds 
 
Property 
COMPOUNDS 
1 2 3 4 5 6 7 8 9 
isoniazid 
Log P 0.74 -0.15 0.90 0.28 1.08 1.10 1.10 -1.89 -0.97 
Polar Surface area 
(Angstroms2) 
55.12 81.43 55.12 100.94 55.12 55.12 55.12 92.39 68.01 
Number of atoms 11 14 12 13 11 11 11 25 10 
Molecular Weight 150.18 194.19 184.63 181.15 215.05 215.05 215.05 345.38 137.14 
Number of oxygen 
& nitrogen atoms 
3 5 3 6 3 3 3 7 4 
Number of –OH 
and –NHn 
3 3 3 3 3 3 3 4 3 
Violations of Rule 
of Five 
0 0 0 0 0 0 0 0 0 
Number of 
Rotatable Bonds 
1 3 2 2 1 1 1 3 1 
Molecular Volume 
(Angstroms3) 
143.28 171.25 157.06 150.05 144.60 144.60 144.60 301.13 122.56 
Minimum 
Inhibitory  
Concentration 
(µgram/milliliter) 
35.0 35.0 35.0 35.0 65.9 29.5 21.5 16.7 14.7 
Log BB -0.563 -1.01 -0.541 -1.31 -0.513 -0.485 -0.485 -1.07 -0.973 
BB 0.273 0.0977 0.288 0.0487 0.307 0.327 0.327 0.0857 0.106 
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Oral administration is the method of choice to insert a drug in humans [20]. The portion of drug 
administered that is absorbed intact depends on various processes as well as membrane permeability [20]. With 
membrane permeation as a common requirement for oral bioavailability, other estimated interactions of 
physicochemical descriptors and intestinal absorption can be used for studies of drug structure-bioavailability 
[20].  Lipophilicity is defined as the affinity of a drug molecule for a lipophilic environment and is a key 
property in the transport processes of drugs including intestinal absorption, membrane permeability, protein 
binding, and distribution among tissues [20].   Aqueous solubility is a vital property that will influence drug 
release and its permeability through biological membranes and absorption in humans [20].  Consequently, it is 
important to estimate water solubility from molecular structure and physicochemical descriptors [20].  
Tuberculosis can enter the central nervous system with high morbidity and mortality [15]. Previous studies have 
determined means to estimate drug penetration into the central nervous system (as Log Cbrain/Cblood or Log 
BB) and that equation {1} can be applied effectively utilizing polar surface area (PSA) and Log P [21]: 
 
                          Log BB = -0.0148(PSA) + 0.152(Log P) + 0.139                       {1} 
 
Values of Log BB and corresponding BB ratios for compounds 1 to 9 are shown in Table 1.Values of 
BB (Cbrain/Cblood) range from 0.0487 (compound 4) to 0.327 (compounds 7 and 8).Although values of BB 
vary for these compounds, the Grubb’s test (extreme studentized deviate) [22, 23] shows no outliers in these 
numerical values of BB, inclusive of isoniazid. Notably the penetration of the central nervous system (CNS) by 
compounds 1, 3, 5, 6, and 7 is greater (by values of BB) than that for first-line tuberculostat isoniazid. Clearly, 
the judicious choice of structure design can improve the vital ability of CNS penetration for clinical treatment of 
CNS tuberculosis.  
Grubb’s test for outliers [22, 23] indicates no outliers within values of Log P, polar surface area, number of 
oxygen & nitrogen atoms, number of rotatable bonds, and Log BB values (see Table 1).  
Comparison of all properties (Table 1) for all nine compounds, even though the numerical values vary, Pearson r 
correlation of compound to other compounds indicates a very strong positive relationship r > 0.9700. One-way 
ANOVA analysis of all molecular properties for all compounds indicate that the means of the numerical values 
for each compound are essentially equal (P=.98) [22, 23].Biological activity, used in drug development, 
describes the beneficial or the adverse effects of a drug on living tissue and this activity is expressed through the 
agents pharmacophore.  Biological activity is a crucial expression of the agent’s possible uses in any medical 
application. Compounds may show some adverse and toxic effects which may prevent their clinical application 
[18, 19, 20].  
Table 2 shows the distribution of bioactivity scores of all nine compounds for the six most important 
categories of drugs (GPCR ligands, ion channel modulators, kinase inhibitors, nuclear receptor ligands, protease 
inhibitors, other enzyme inhibitors). The range for average drug-like molecules for each category is provided for 
each category in parenthesis (see Table 2).  Note that all nine compounds fall within the drug-like optimal range 
for each of the six categories of drugs.Although the numerical values of bioactivity for this group of agents vary 
and are diverse, the Pearson r correlation for compound to compound is greater than 0.8900, indicating a very 
strong positive relationship [22, 23].  However, the median of numerical values for each compound are not 
equal by Kruskal-Wallis test (P=.002).  In addition, the means of numerical values for each compound are not 
equal to that of other compounds, by one-way ANOVA (P<0.001). Consequently, for these hydrazide 
compounds, including isoniazid, the bioactivity scores are favorable, diverse, and vary but not identical from 
compound to compound. 
 
Table 2 Bioactivity of Compounds Compared to Drug Categories 
 
Category 
(optimum range) 
COMPOUNDS 
1 2 3 4 5 6 7 8 9 
isoniazid 
GPCR ligand 
(-1.5 to 0.50) 
-1.40 -1.04 -1.41 -1.31 -1.65 -1.58 -1.58 -0.10 -1.39 
Ion channel 
modulator 
(-2.0 to 0.50) 
-1.59 -1.13 -1.43 -1.22 -1.68 -1.61 -1.61 -0.61 -1.45 
Kinase inhibitor 
(-2.0 to 0.50) 
-1.29 -1.02 -1.49 -1.16 -1.44 -1.37 -1.37 -0.02 -1.05 
Nuclear receptor 
ligand 
(-2.0 to 0.50) 
-2.04 -1.24 -2.23 -1.76 -2.27 -2.31 -2.31 -0.71 -2.33 
Protease inhibitor 
(-2.0 to 0.50) 
-1.25 -0.83 -0.84 -1.15 -1.54 -1.45 -1.45 -0.27 -1.23 
Enzyme inhibitors 
(-1.5 to 0.50) 
-0.84 -0.48 -0.66 -0.73 -0.98 -0.90 -0.90 0.12 -0.66 
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Pattern Recognition and Comparative Potency 
Pattern recognition focuses on the recognition of patterns and regularities in data, identifying 
underlying relationships [22, 23]. Cluster analysis or clustering is technique of pattern recognition, which groups 
(drugs) a set of objects in such a way that objects in the same group (or cluster) are more most similar to each 
other than to those found in other groups (clusters) [22, 23].  Hierarchical cluster analysis is based on objects 
(drugs)  being more related to nearby objects than to objects farther away. Single-linkage clustering is based on 
grouping clusters combining two clusters that contain the closest pair of elements or when the two clusters 
whose two closest members have the smallest distance [23]. 
Cluster analysis applied in drug development can identify, utilizing molecular properties, all agents that 
are most similar. Applied in this study, based on molecular properties (see Table 1), hierarchical cluster analysis 
identified which compounds have highest level of similarity (see Figure 2).  The outcome presented in Figure 2 
as a vertical dendrogram, beginning at super node A, under node B compounds 4 and 9 (isoniazid) are 
determined to be most similar. Under node C, compounds 1, 7, 8, 5, and 6 are determined to have the highest 
similarity. However, under node C, compound 2 is determined to be distinct from 1, 7, 8, 5, 6, and 3. Therefore, 
compound 4 may be most similar to isoniazid in clinical treatment of tuberculosis.  
 
 
Figure 2 Vertical dendrogram of molecular properties (see Table 1), utilizing single linkage and 
Euclidean distance.  Beginning with super node A, the compounds are distinguished into node B having 
compounds 4 and 9 (isoniazid).  Compounds 1, 7, 8, 5, and 6 are seen to be most similar to each other, with 
compound 3 determined to be distinct.  Compound 2 under node C, is determined to be distinct from compounds 
1, 7, 8, 5, 6, and 3. 
 
The corresponding values of MIC (compound concentration when only 50% of the bacteria in culture 
are viable) for these hydrazide compounds are presented for comparison to isoniazid and for evaluation based on 
molecular structure (see Figure 3). The numerical values of MIC for hydrazide compounds 1, 2, 3, and 4 are 
essentially the same at 35 micrograms/milliliter.  Interestingly, the substituents for compounds 1, 2, 3, and 4, are 
diverse, having (see Figure 1): Compound 1) methyl group (meta); Compound 2) acetate group (meta); 
Compound 3) chloromethyl (para); Compound 4) nitro group (para).  Notably, the substituents are in meta or 
para position to the hydrazide group, thus avoiding any steric hindrance to the action of the hydrazide moiety (-
C(=O)NHNH2). Compound 5 has the largest numerical value of MIC, requiring the greatest concentration of 
compound to achieve 50% kill rate of bacteria in culture. The bromine atom (-Br) is in the ortho position 
relative to the hydrazide group, potentially influencing bioactivity of the compound due to steric hindrance.  
Compounds 6, 7, and 8 have the lowest numerical values of MIC and very close to that for isoniazid (14.7 
micrograms/milliliter). Both compounds 6 and 7 have bromine atoms as substituents, as does compound 5, 
however the bromine atoms are in meta position (compound 6) and para position (compound 7) relative to the 
hydrazide group with no steric hindrance as a potential hurdle to bioactivity. 
Compound 8 is unique; it is a hydrazide derivative of ciprofloxacin [15, 16]. Ciprofloxacin is a broad-
spectrum antibiotic of the fluoroquinolone class active against both Gram-positive and Gram-negative bacteria. 
Ciprofloxacin inhibits DNA gyrase, and topoisomerase IV, necessary to separate bacterial DNA [24].  
Considering that the spectrum of activity includes most strains of bacterial pathogens responsible for respiratory, 
urinary tract, gastrointestinal, and abdominal infections [24], it follows that the bioavailability of ciprofloxacin 
is substantially favorable. This hydrazide derivative (compound 8) has numerical values of Log BB and Log P 
very close to that of isoniazid (log P for both are less than zero), these facts may provide some clue as to the 
similarity in MIC values.  
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Figure 3 Values of MIC for all hydrazide compounds 1 to 8.  Compound 9 is isoniazid. 
 
Path analysis is a straightforward extension of multiple regression.  Two or more specified causal 
hypotheses can be represented in which the relative sizes of path coefficients in the output path relates which of 
them is better supported by the data [25, 26, 27].  The larger the numerical value of the path coefficient, the 
greater the support for the caused variable (MIC in this study).  
Results of path analysis for causal relationship of molecular properties for minimum inhibitory 
concentration (MIC) is presented in Table 3. The largest coefficients indicate the property determined to be of 
highest causal relationship of MIC of this tuberculostats. Clearly, the number of oxygen and nitrogen atoms 
have the greatest causal relationship to MIC having path coefficient of 5.578.  This is followed second by Log P 
property, having a path coefficient of 1.490.  This study elucidates the properties most important for 
achievement of favorable (lower) values of MIC and will assist in further drug development of hydrazide 
compounds for treatment of tuberculosis. 
 
Table 3 Path Analysis for Summary Causal Relationship of Properties to MIC 
Variable Caused 
(Minimum inhibitory concentration) 
Causing Variable Path Coefficient 
MIC Log P 1.490 
MIC Polar Surface Area 
(Angstroms2) 
-3.832 
MIC Number of Atoms -2.000 
MIC Molecular Weight -0.181 
MIC Number of Oxygen 
& Nitrogen Atoms 
5.578 
MIC Number of Rotatable Bonds 0.257 
MIC Molecular Volume 
(Angstroms3) 
0.630 
 
Multiple Regression Analysis for Prediction 
Multiple regression is a statistical tool that allows you to examine how multiple independent variables 
are related to a dependent variable. Once you have identified how these multiple variables relate to your 
dependent variable, you can take information about all of the independent variables and use it to make much 
more powerful and accurate predictions concerning these variables [22, 23]. For equation {2}, MW is molecular 
weight, PSA is polar surface area, nAtoms is number of atoms, nON is number of oxygen & nitrogen atoms, 
nOHNH is number of hydroxyl & amine groups, nRotB is number of rotatable bonds, and volume is molecular 
volume.  
 
  MW = -3023.0 + 10.243(PSA) – 686.97(nAtoms) + 186.22(nON) + 840.35(nOHNH) + 
 
                                                                 44.217(nRotB) + 49.144(volume)                         {2} 
 
Value of R
2
 is 1.00, indicating that the model explains 100% of the variance within the model.  The P 
values for each variable and constant are (P< .0001), therefore the model indicates that the constant (-3023.0) 
and all independent variables contribute significantly to this model [23]. The study and design of new drugs to 
combat the appearance of drug resistant tuberculosis is a vital undertaking to maintain effective clinical 
treatment of this bacterial pathogen. 
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IV. Conclusion 
The study of novel drugs for the treatment of tuberculosis is necessary due to the appearance of the 
multidrug-resistant and extensively drug-resistant tuberculosis.  This study presents eight hydrazide compounds 
shown to inhibit growth of Mycobacterium tuberculosis and compares their molecular properties and potency to 
the first-line drug isoniazid. The minimum inhibitory concentration (MIC) for reduction of bacteria viability to 
50% of origin ranged from 16.7 micrograms/milliliter to 35.0 micrograms/milliliter for compounds 1 to 8.  
Although the molecular properties of all nine hydrazide compounds (including isoniazid) varied in numerical 
values, the Pearson r correlation of compound to other compounds showed a very strong positive relationship r 
> 0.9700.  All nine compound showed zero violations of the Rule of 5. Compounds 1, 3, 5, 6, and 7 have greater 
penetration into the CNS, having values of BB greater than that of Isoniazid at 0.106.  Hierarchical cluster 
analysis determined that compound 4 is most similar to isoniazid.  Multiple regression analysis determined a 
mathematical model explaining 100% of variance in the variables and capable of predicting descriptor values for 
similar agents.  Path analysis determined that number of oxygen and nitrogen atoms (path coefficient = 5.578) 
and Log P (path coefficient = 1.490) have highest causal relationship to values of MIC. The design and 
development of new tuberculostats are of vital importance for effective treatment of the spreading incidents of 
drug resistant Mycobacterium tuberculosis. 
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